Purexa™ OdT — mRNA Affinity Membrane Product Update

Dynamic Binding Capacity (DBC) vs Flowrate

DBC vs Flowrate at Varying mRNA Sizes

mRNA Recovery vs Flowrate

Purilogics is currently developing a novel and first-in-market high-capacity, -selectivity, and -throughput affinity membrane for the purification of mRNA. The research, development, and testing for this product, Purexa™ OdT, is supported by a grant awarded to Purilogics from the Small Business Innovation Research (SBIR) Direct to Phase II program of the National Institutes of Health (NIH). Read our previous post to learn more about this award and our goals for the Purexa™ OdT mRNA affinity membrane. In this post, we aim to provide a performance update on Purexa™ OdT and highlight how the product currently performs against leading commercially available mRNA affinity resins.